Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor

J Thorac Oncol. 2016 Feb;11(2):e21-3. doi: 10.1016/j.jtho.2015.08.001. Epub 2015 Dec 18.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / genetics
  • Adenocarcinoma of Lung
  • Anaplastic Lymphoma Kinase
  • Crizotinib
  • Drug Resistance, Neoplasm
  • ErbB Receptors / genetics*
  • Female
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Middle Aged
  • Mutation*
  • Protein Kinase Inhibitors / therapeutic use*
  • Proto-Oncogene Proteins c-met / genetics*
  • Pyrazoles / therapeutic use*
  • Pyridines / therapeutic use*
  • Receptor Protein-Tyrosine Kinases / genetics

Substances

  • Protein Kinase Inhibitors
  • Pyrazoles
  • Pyridines
  • Crizotinib
  • Anaplastic Lymphoma Kinase
  • EGFR protein, human
  • ErbB Receptors
  • MET protein, human
  • Proto-Oncogene Proteins c-met
  • Receptor Protein-Tyrosine Kinases